EA201892071A1 - Способ профилактики болезни "трансплантат против хозяина" - Google Patents
Способ профилактики болезни "трансплантат против хозяина"Info
- Publication number
- EA201892071A1 EA201892071A1 EA201892071A EA201892071A EA201892071A1 EA 201892071 A1 EA201892071 A1 EA 201892071A1 EA 201892071 A EA201892071 A EA 201892071A EA 201892071 A EA201892071 A EA 201892071A EA 201892071 A1 EA201892071 A1 EA 201892071A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- gvhd
- transplantate
- owner
- disease
- prevention
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 4
- 230000000735 allogeneic effect Effects 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 238000011476 stem cell transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Способ профилактики РТПХ у пациента-человека, включающий в себя введение пациенту, страдающему от РТПХ или подверженному риску РТПХ, гуманизированного антитела со специфичностью связывания с интегрином α4β7 человека, причем пациенту-человеку проведена или будет проведена аллогенная трансплантация стволовых клеток, и при этом режим дозирования предотвращает, улучшает или устраняет РТПХ.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662307896P | 2016-03-14 | 2016-03-14 | |
PCT/US2017/022065 WO2017160699A2 (en) | 2016-03-14 | 2017-03-13 | Method of preventing graft versus host disease |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201892071A1 true EA201892071A1 (ru) | 2019-03-29 |
Family
ID=58448610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201892071A EA201892071A1 (ru) | 2016-03-14 | 2017-03-13 | Способ профилактики болезни "трансплантат против хозяина" |
Country Status (13)
Country | Link |
---|---|
US (1) | US20200002422A1 (ru) |
EP (1) | EP3430052A2 (ru) |
JP (2) | JP2019508448A (ru) |
KR (1) | KR20180120706A (ru) |
CN (2) | CN116327920A (ru) |
AU (1) | AU2017234009B2 (ru) |
BR (1) | BR112018068628A2 (ru) |
CA (1) | CA3017743A1 (ru) |
EA (1) | EA201892071A1 (ru) |
IL (1) | IL261750B2 (ru) |
MA (1) | MA44408A (ru) |
MX (1) | MX2018011169A (ru) |
WO (1) | WO2017160699A2 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109414502A (zh) | 2016-06-12 | 2019-03-01 | 千禧制药公司 | 治疗炎症性肠病的方法 |
JP7422667B2 (ja) | 2018-02-08 | 2024-01-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 同種造血幹細胞移植のための方法 |
US20230165958A1 (en) * | 2020-04-27 | 2023-06-01 | Children's Hospital Medical Center | Precision Dosing Regimen |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | ドメイン‐変性不変部を有する抗体 |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
MX9706049A (es) | 1995-02-10 | 1998-02-28 | Leukosite Inc | Adresinas vasculares mucosas y sus usos. |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
EP1507756B1 (en) | 2002-05-24 | 2015-07-22 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
JP4611746B2 (ja) | 2002-11-18 | 2011-01-12 | ケモセントリックス, インコーポレイテッド | アリールスルホンアミド |
NL1027975C2 (nl) | 2004-01-09 | 2005-12-23 | Pfizer | Antilichamen tegen MAdCAM. |
KR101364276B1 (ko) | 2004-09-03 | 2014-02-20 | 제넨테크, 인크. | 인간화 항-베타7 길항제 및 그의 용도 |
AU2006316629A1 (en) | 2005-11-17 | 2007-05-31 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with alpha 4 beta 7 integrin |
CN103382222B (zh) * | 2009-03-20 | 2016-12-28 | 安姆根有限公司 | α-4-β-7异二聚体特异性拮抗剂抗体 |
KR102493433B1 (ko) * | 2011-05-02 | 2023-01-27 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-α4β7 항체에 대한 제형 |
UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
MX370199B (es) * | 2012-02-16 | 2019-12-05 | Santarus Inc | Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a). |
MX2014015830A (es) * | 2012-06-21 | 2015-03-05 | Compugen Ltd | Anticuerpos lsr y usos de los mismos para el tratamiento de cancer. |
WO2016027253A1 (en) * | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
MA41636A (fr) * | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
JP2019512493A (ja) * | 2016-03-14 | 2019-05-16 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 移植片対宿主病の処置または予防の方法 |
-
2017
- 2017-03-13 US US16/084,383 patent/US20200002422A1/en active Pending
- 2017-03-13 WO PCT/US2017/022065 patent/WO2017160699A2/en active Application Filing
- 2017-03-13 JP JP2018548207A patent/JP2019508448A/ja active Pending
- 2017-03-13 EA EA201892071A patent/EA201892071A1/ru unknown
- 2017-03-13 EP EP17714328.6A patent/EP3430052A2/en active Pending
- 2017-03-13 IL IL261750A patent/IL261750B2/en unknown
- 2017-03-13 KR KR1020187027194A patent/KR20180120706A/ko not_active Application Discontinuation
- 2017-03-13 CN CN202211678697.9A patent/CN116327920A/zh active Pending
- 2017-03-13 MX MX2018011169A patent/MX2018011169A/es unknown
- 2017-03-13 MA MA044408A patent/MA44408A/fr unknown
- 2017-03-13 CA CA3017743A patent/CA3017743A1/en active Pending
- 2017-03-13 AU AU2017234009A patent/AU2017234009B2/en active Active
- 2017-03-13 CN CN201780017510.1A patent/CN109071660A/zh active Pending
- 2017-03-13 BR BR112018068628A patent/BR112018068628A2/pt unknown
-
2022
- 2022-07-22 JP JP2022116951A patent/JP2022163078A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2018011169A (es) | 2018-12-06 |
CN109071660A (zh) | 2018-12-21 |
EP3430052A2 (en) | 2019-01-23 |
WO2017160699A2 (en) | 2017-09-21 |
WO2017160699A3 (en) | 2017-11-23 |
US20200002422A1 (en) | 2020-01-02 |
JP2022163078A (ja) | 2022-10-25 |
MA44408A (fr) | 2019-01-23 |
CN116327920A (zh) | 2023-06-27 |
KR20180120706A (ko) | 2018-11-06 |
JP2019508448A (ja) | 2019-03-28 |
IL261750B2 (en) | 2024-07-01 |
AU2017234009A1 (en) | 2018-09-27 |
IL261750A (en) | 2018-10-31 |
BR112018068628A2 (pt) | 2019-07-30 |
AU2017234009B2 (en) | 2024-06-06 |
CA3017743A1 (en) | 2017-09-21 |
IL261750B1 (en) | 2024-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017016502A (es) | Anticuerpos contra cd40 con actividad agonista mejorada. | |
MX2022002504A (es) | Anticuerpos para cd40. | |
EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
PH12015500114A1 (en) | HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF | |
MX2018008557A (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos. | |
EA201691683A1 (ru) | Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме | |
PH12015501558A1 (en) | Human antibodies to respiratory syncytial virus f protein and methods of use thereof | |
UA109658C2 (xx) | Антитіло проти cgrp | |
EA201591198A1 (ru) | Антитела к gdf15 | |
GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
UA107600C2 (uk) | АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ | |
MX2018010672A (es) | Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada. | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
WO2015050959A8 (en) | Anti-kit antibodies and methods of use thereof | |
EA201790439A1 (ru) | Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами | |
MX2017009694A (es) | Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l). | |
EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
MX2018012939A (es) | Moleculas de union especificas para receptor fc gamma humano iia y usos de las mismas. | |
WO2014028668A3 (en) | Stem cell enhancing therapeutics | |
EA201892525A1 (ru) | Конструкции днк-антител для применения против pseudomonas aeruginosa | |
WO2016057683A3 (en) | Novel anti-nodal antibodies and methods of using same | |
NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
EA201892071A1 (ru) | Способ профилактики болезни "трансплантат против хозяина" | |
MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. |